Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417021 | 0.82 | CCR1 (0.40) | HTR2AHTR2COGA | |
| SCHEMBL5615371 | 0.81 | — | — | |
| SCHEMBL855838 | 0.81 | HPGD (0.36) | IRAK4HTR2AHTR2COGA | |
| SCHEMBL413086 | 0.81 | ENPP3 (0.39) | HTR2AHTR2CCNR2 | |
| SCHEMBL30643452 | 0.80 | KCNH2 (0.35) | OGA | |
| SCHEMBL12147023 | 0.78 | PARP1 (0.34) | OGA | |
| SCHEMBL29533363 | 0.78 | HTR2C (0.35) | HTR2COGA | |
| SCHEMBL5055520 | 0.77 | PTGER4 (0.38) | — | |
| SCHEMBL24198308 | 0.77 | CNR2 (0.41) | IRAK4HTR2AHTR2CAPPCNR2 | |
| SCHEMBL15280186 | 0.75 | CCR1 (0.37) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110016030-B | Preparation method of 5-fluoro-1H-pyrrole- [2,3-b ] pyridine-4-formaldehyde | 南京合巨药业有限公司 | 2021-02-09 | — | — | CN | claimed |
| US-7514448-B2 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514448-B2 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-07 | — | — | US | disclosed |
| CN-101014597-A | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMA (US) | 2007-08-08 | — | — | CN | disclosed |
| WO-2007053094-A1 | CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| EP-1756108-A2 | AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20060003968-A1 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-05 | — | — | US | disclosed |
| WO-2005103050-A2 | AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003968-A1 | Azaindoles useful as inhibitors of rock and other protein kinases | ROCK2, ROCK1, TNK2 | IRAK4 2040/4885HTR2A 2480/4885HTR2C 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.